NCT06726564 A Study of MT027 in Patients with Pleural Malignant Tumors

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 18 participants in total. It began in 2024-05-15 with a primary completion date of 2026-05.

Brief Summary

This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.

Eligibility Criteria

Inclusion Criteria: 1. voluntarily participate in the study and sign informed consent; 2. age over 18 years old (including the cut-off value), regardless of gender; 3. advanced malignant solid tumor pathologically and/or histologically diagnosed with malignant pleural effusion requiring drainage confirmed by histopathology or cytopathology (metastatic or primary); 4. the original pleural cavity malignant tumor after standard treatment failure, or top treatment; 5. signed informed consent not line within a month before the chest cavity medicine injection, but does not exclude the diagnostic puncture; 6. The subjects voluntarily provided sufficient tumor cells in the pathological section of the primary lesion and/or pleural effusion for B7-H3 expression detection, and the tumor cells in the pathological section of the primary lesion or malignant pleural effusion were positive for B7-H3 expression; 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2; 8. within 7 days before treatment laboratory meet the following criteria: Routine blood (14 days) : 1. Absolute neutrophil count (ANC) ≥1.5×109 /L; 2. platelet count (PLT) or 80 x 109 / L; 3. hemoglobin (HGB) or 80 g/L (allowing blood transfusion and use erythropoiesis agent). The presence of active bleeding or other ongoing conditions that result in increased red-cell destruction or impaired production may require repeated transfusions or red-cell therapy, and patients had to discuss their eligibility with the sponsor on an individual basis before enrollment.) ; Liver: 1. total bilirubin (TIBC) or less 2 times the upper limit of the normal range (ULN); 2. no liver metastasis, AST and ALT 3 x ULN or less; ALT and AST≤5 times ULN in the presence of liver metastasis; Kidney: 1. Serum creatinine (Cr) ≤ 2 times ULN; Or creatinine clearance (CrCL) ≥ 50 mL/min (estimated by Cockcroft-Gault formula); Blood coagulation function: 2. international standardization ratio (INR) or prothrombin time (PT) 1.3 x ULN or less; 3. Partial activated thromboplastin time (APTT) ≤ 1.5 times ULN; 9) toxicity from previous systemic therapy returned to grade 1 or less or to baseline before the first dose (except alopecia); 10) Fertile men and women of childbearing age must agree to use reliable contraception from the time they provide informed consent until 180 days after the last dose of MT027 cell injection; Women of childbearing age included those who were premenopausal and those within 2 years of menopause. Exclusion Criteria: 1. known allergy to the study drug or its excipients; 2. patients with pleural puncture contraindications or won't benefit from intrathoracic medication; 3. any antineoplastic drugs other than systemic antineoplastic therapy that the subject has been taking stably and any treatment that may have an effect on the control of pleural effusion (other than diagnostic puncture or thoracentesis for investigational treatment); 4. in the first test within 2 weeks before treatment received radiotherapy. 5. major surgery is performed within 4 weeks before the first trial treatment and the patient has not fully recovered; 6. are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 1 week before the first trial treatment. 7. participated in other drug clinical trials within 4 weeks before screening; 8. always had targeted B7 - H3 CAR - T cells treatment; 9. patients with active systemic or pulmonary infection, coagulopathy and other major diseases; 10. with severe heart, lung, liver and renal insufficiency; Cardiac function: grade 3 or above according to the New York Heart Association (NYHA) criteria; Liver function: Child - Puge classification standard for grade C or above; Renal function: chronic kidney disease (CKD) stage 4 or above; Renal insufficiency stage Ⅲ or above; Pulmonary function: severe symptoms of respiratory failure involving other organs; 11. patients with severe autoimmune diseases; 12. recipients of previous allogeneic tissue/solid organ transplantation; 13. who received a live vaccine within 2 weeks before the first cell therapy or were scheduled to receive a live vaccine during the study; 14. active HBV infection; Or hepatitis C virus infection (defined as positive for HCV antibody, allowed if HCV-RNA was below the lower limit of detection); Or human immunodeficiency virus infection (defined as HIV antibody positive); Or positive treponema pallidum antibody; 15. subjects had severe neurocognitive impairment as judged by the investigator; 16. pregnant or lactating women; 17. There were any clinical or laboratory abnormalities or other reasons considered by the investigator to preclude participation in the study.

Contact & Investigator

Frequently Asked Questions

Related Trials